EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Shared Decision‐Making in Haemophilia Involves More Treatment Differentiators in 2026

Quentin Van Thillo, Guy Young, Cedric Hermans

Haemophilia · 01.11.2026

DOI: 10.1111/hae.70440 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Haemophilia, online erschienen am 01.11.2026. Verfasst von Quentin Van Thillo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Haemophilia Centre, Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Shared decision‐making regarding treatment choice in haemophilia care has become increasingly more complex and essential due to the availability of several innovative therapeutics that are characterized by their own advantages and limitations, which need to be tailored to individual patient needs.

Aim

We aim to complement the World Federation of Haemophilia (WFH) Shared Decision‐Making Tool by providing an update on the key differentiators that need to be considered by clinicians when discussing treatment options with their patients.

Methods

Based on the experience of three physicians from haemophilia treatment centres in Belgium and the USA with expertise in both adult and paediatric haemophilia, we have written a narrative framework for shared decision‐making in haemophilia.

Results

We identified fifteen differentiators including treatment class, burden, efficacy, safety, monitoring needs, access, and broader patient‐centred outcomes beyond haemostasis.

Conclusion

Using these updated treatment differentiators in conjunction with the WFH tool, physicians are better equipped to engage in shared decision‐making discussions with their patients with the ultimate goal of attaining more personalised and equitable care. Key Points The increasing number of treatment options for haemophilia requires an update of the key treatment differentiators for shared decision‐making. These differentiators complement the existing WFH Shared Decision‐Making Tool and help physicians engage in more comprehensive shared decision‐making discussions.

Schlagwörter

Stichwörter der Autor:innen

Hemophilia Bantibodiesbispecificblood coagulation factorsdecision makingemophilia Agenetic therapypatient‐centered careshared

Autor:innen und Institutionen

  • Haemophilia Centre, Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Haemostasis and Thrombosis Unit, Division of Adult Haematology, Cliniques Universitaires Saint-Luc, Université Catholique De Louvain (UCLouvain), Brussels, Belgium.
  • Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
  • World Federation of Haemophilia, Montreal, Canada.

Zitieren

APA

Van Thillo, Q., Young, G., & Hermans, C. (2026). Shared Decision‐Making in Haemophilia Involves More Treatment Differentiators in 2026. Haemophilia. https://doi.org/10.1111/hae.70440

Vancouver

Van Thillo Q, Young G, Hermans C. Shared Decision‐Making in Haemophilia Involves More Treatment Differentiators in 2026. Haemophilia. 2026. doi:10.1111/hae.70440

BibTeX
@article{VanThillo2026,
  author = {Van Thillo, Quentin and Young, Guy and Hermans, Cedric},
  title = {Shared Decision‐Making in Haemophilia Involves More Treatment Differentiators in 2026},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70440}
}
Kostenlos starten →